Journal of Pharmacology, Genetics and Molecular Biology (JPGMB)
ISSN: 3049-3757 | Vol. 01, Issue-06, Nov-Dec, 2025

Pathophysiological Insights into Parkinson's Disease Progression

Kamini Verma[1], Gitika Verma[2], Pankaj Kumar Sahu[3], Pratiksha fulzele[3], Vinay Sagar Verma[2*]

[1]Kamla Institute of Pharmaceutical Sciences, Junwani, Bhilai, Durg, Chhattisgarh, 490020, India

[2]Shri Shankaracharya Technical Campus, Faculty of Pharmaceutical Sciences, Junwani, Bhilai, Durg, Chhattisgarh, 490020, India
[3]M J College, Kohka, Bhilai, Durg, Chhattisgarh, 490023, India

***Corresponding Author E-mail: vinaysagarverma@gmail.com**

ABSTRACT

Parkinson disease (PD) is a progressive and multifactorial neurodegenerative disease, which is mainly caused by the selective destruction of dopaminergic neurons in the substantia nigra pars compacta, and causes the typical motor symptom of bradykinesia, resting tremor, rigidity, and postural instability. In addition to these motor defects, PD has a wide range of non-motor symptoms, such as cognitive, mood, sleep, and autonomic deficiency, all of which decrease the quality of life of patients considerably. PD has a complicated pathophysiology comprising genetic predisposition (e.g., SNCA, LRRK2, PARK gene mutations), environmentally triggered, mitochondrial dysfunction, oxidative stress, chronic neuroinflammation, and aggregation and prion-like propagation of α-synuclein. Neurotoxin-induced, genetic, and α-synuclein pre-formed fibril (PFF) systems have proven essential in the understanding of these mechanisms and as a result of the knowledge led to an understanding of the loss of dopaminergic neurons, misfolding of α-synuclein, glial-mediated neuroinflammation, and both motor and non-motor symptoms. Moreover, the models provide critical platforms on preclinical analysis of therapeutic interventions, such as antioxidant therapies, anti-aggregates, immunomodulatory therapies, and those that promote non-motor symptoms and thus improved clinical outcomes and development of holistic disease-modifying interventions.

Key Words:

Parkinson's Disease, Dopaminergic Degeneration, A-Synuclein Aggregation, Neuroinflammation, Neurotoxin Models, Genetic Models, Pre-Formed Fibril Models, Non-Motor Symptoms.

Article History:

Received on Sep 11, 2025

Revised on Oct 21, 2025

Accepted on Nov 21, 2025

Published on Dec 23, 2025

DOI: https://doi.org/10.64062/JPGMB.Vol1.Issue6.3

1. INTRODUCTION

Parkinson disease (PD) is a progressive neurodegenerative condition, the main feature of which is the selective depletion of dopaminergic neurons in the substantia nigra pars compacta causing the typical motor hypomimia of bradykinesia, tremor on rest, rigidity and postural weakness. In addition to these motor deficits, PD is gradually becoming a multisystem condition with non-motor symptoms such as cognitive impairments, mood swings, sleeping problems, and autonomic dysreflexia, which has dire consequences on the quality of life of patients[1]. PD pathophysiology is multiple-factorial and intricate, including genetic

predispositions, environmental factors, mitochondrial impairments, oxidative stress, neuroinflammation, and atypical protein aggregation, especially of α-synuclein. Although decades of study have been devoted to understanding the mechanisms of PD progression, the exact order of molecular and cellular processes is still not clearly known, and understanding the mechanisms underlying the disease is the key to the creation of effective disease-modifying therapy.



Figure 1: Parkinson's Disease (PD)

Animal models have become irreplaceable in the study of the pathophysiology of PD. The neurotoxin-induced, genetic and alpha-synuclein pre-formed fibril (PFF) models have yielded important studies on dopaminergic degeneration, alpha-synuclein aggregation, neuroinflammatory response and the course of motor and non-motor symptoms[2]. These models can be used to experimentally study disease mechanisms in an easily controlled experimental manner and they can also be used in preclinical studies of neuroprotective strategies and therapeutic interventions. A combination of the results of these various models can assist to fill the gaps between the molecular pathology and clinical manifestation, which would eventually benefit the knowledge on PD progression and the direction of future research.

1.1. Background Information and Context

The second most prevalent neurodegenerative disorder in the world is the Parkinson disease, which is very common in millions of people, most of the elderly population. It has a multifactorial etiology with complicated interactions between genetic mutations including SNCA, LRRK2 and PARK genes as well as environmental risk factors such as exposure to pesticides and neurotoxins[3]. The pathological features of PD include the destruction of dopaminergic neurons and the development of Lewy bodies that contain alpha-synuclein[4]. The pathological alterations are the initiators of a series of neurodegenerative events, such as mitochondrial dysfunction, oxidative stress, synaptic damages, and neuroinflammation that play a role in the characteristic motor and non-motor symptoms. Knowledge of these

underlying mechanisms is critical in designing treatment modalities that go beyond symptom control to treatment that aims at reducing the disease at its core.

1.2. Objectives of the Review

This review aims to:

- To examine the pathophysiological mechanisms underlying Parkinson's disease, including dopaminergic degeneration, α-synuclein aggregation, and neuroinflammation.
- To evaluate the utility and limitations of neurotoxin-induced, genetic, and α-synuclein PFF animal models in replicating PD pathology and symptomatology.
- To analyze the molecular and cellular pathways contributing to motor and non-motor symptoms of PD.
- To assess the role of animal models in testing therapeutic interventions and neuroprotective strategies targeting PD progression.
- To identify gaps in current preclinical models and suggest directions for developing more translationally relevant systems for future research.

1.3. Importance of the Topic

The explanation of the pathophysiological processes of PD is the most significant in relation to both the basic neuroscience studies and clinical practice. Greater insight into the evolution of the disease would allow discovering early biomarkers, developing the neuroprotective and disease-modifying therapy, and enhancing the control over both motor and non-motor symptoms[5]. Since PD is increasingly more prevalent, and its effects on patient quality of life are overwhelming, studies on its pathophysiology continue to be a high priority in neurology and neurodegenerative disease studies.

1. ANIMAL MODELS OF PARKINSON'S DISEASE: RESEARCH STUDIES, METHODOLOGIES, AND EVALUATION

The models most commonly used in the study of Parkinson disease include neurotoxin, genetic, and 0-synuclein PFF models and they reproduce the characteristics of loss of dopaminergic, motor deficits and protein aggregation. Targeted neuronal degeneration has been induced by neurotoxins such as 6-OHDA and MPTP, genetic models have shown alpha -synuclein-associated neurodegeneration and PFF models have reproduced prion-like pathology dissemination[6]. The models can be used to explain the molecular processes, clinical trials, and disease pathophysiology. Although they can provide good control over the environment and flexibility of experiments, they do not comprehensively represent the complexity of human PD, particularly non-motor symptoms, and differences between species may limit relevance with humans.



Figure 2: Animal Models of Parkinson's Disease[7].

2.1. Key Research Studies

PD-like loss of dopaminergic, motor, and protein aggregation are recreated using neurotoxin, genetic, and alpha -synuclein PFF models. They are necessary to examine the pathogenesis of diseases, their evolution and the evaluation of possible treatments.

- **Neurotoxin-Induced Models:** The most common models used to cause the degeneration of dopaminergic neurons in rodent models are 6-hydroxydopamine (6-OHDA) and MPTP neurotoxins. These toxins selectively affect the dopaminergic neurons in the substantia nigra leading to motor impairment similar to that found in Parkinson's disease (PD), bradykinesia, rigidity, and postural instability[8]. The models have been essential in the study of the pathophysiology of dopaminergic neuron loss and the testing of possible neuroprotective treatment.
- **Genetic Models:** Transgenic mouse models with mutant alleles of alpha-synuclein e.g. A53T or A30P mutations that are expressed in the mouse brain undergo a progressive neurodegeneration, and develop alpha-synuclein aggregates[9]. These mice gain motor deficits and neuronal pathologic changes that are similar to those observed in human PD, and thus, they can be useful in studying the genetic and molecular basis of α-synuclein-mediated neurodegeneration.
- **Pre-formed Fibrils of α-Synuclein (PFF) Models:** The expression of α-synuclein in rodents leads to aggregation and spread of native α-synuclein by injection of α-synuclein pre-formed fibrils into the brains of rodents[10]. This model recreates the major pathological features of PD, such as the proliferation of alpha-synuclein inclusions throughout non-discrete brain areas and progressive impairment of dopaminergic neurons, which can be used to analyze the disease progression and the possible treatment options.

2.2. Methodologies and Findings

Dopaminergic degeneration, 2 -synuclein aggregation, and prion-like pathology are studied with the help of neurotoxin, genetic and PFF models of PD to explain the mechanisms of the disease. They give platforms on which to test therapies and learn about motor and progressive neuronal impairments.

- **Neurotoxin Models:** The selective destruction of dopaminergic neurons is caused by experimental received neurotoxins such as 6-OHDA and MPTP. These models have contributed to the explanation of the molecular processes of oxidative stress, mitochondrial dysfunction, and neuroinflammation that contribute to the pathophysiology of PD[11]. They are extensively applicable in the assessment of the effectiveness of neuroprotective and symptomatic interventions as well.
- **Genetic Models:** Transgenic mice expressing mutant alpha-synuclein develop Lewy body-like inclusions and progressive motor impairment[12]. These results confirm the importance of α-synuclein aggregation in PD and enable scientists to study the interaction between genes and the environment, along with the pathophysiology of protein misfolding and neuron susceptibility.
- **PFF Models:** Models of PFF-induced models have revealed that pathology of the α-synuclein may propagate cell-to-cell, impairing cellular functions as well as leading to neurodegeneration[13]. This system gives an opportunity to examine the prion-like characteristics of α-synuclein, the inclusion formation dynamics, and the consequential effects on neuronal networks which have close resemblance to the pathology of progressive PD.

2.3. Strengths and Weaknesses

Neurodegeneration and therapies are studied using animal models of PD, which cannot adequately model the complexity of human diseases. Their limitations in utilizing non-motor symptoms and species differences limit their translatability.

- **Strengths:** Animal models offer a controlled experimental set-up in order to investigate PD pathophysiology. They enable researchers to control genetic and environmental factors, investigate neurodegeneration mechanisms and pre-clinically test a possible pharmacological treatment[14].
- **Weaknesses:** Although of use, none of the animal models can replicate comprehensively the complicated clinical and pathological phenotypes of human PD. The neuroanatomy, progression of diseases, and responses of different species may be species-specific, which puts a constraint on generalizing these studies to humans. Further, other models mainly replicate motor features but do not recapitulate non-motor conditions of the disease, including cognitive and autonomic dysfunction[15].

2. PATHOPHYSIOLOGICAL INSIGHTS FROM ANIMAL MODELS OF PARKINSON'S DISEASE

Parkinson disease animal models such as neurotoxin, genetic, and α-synuclein PFF models are essential in the study of the dopaminergic degeneration, α-synuclein aggregation, neuroinflammation, and non-motor symptoms. Neurotoxins such as 6-OHDA and MPTP recapitulate dopaminergic degeneration and motor impairment whereas genetic and PFF models indicate protein misfolding and prion-like propagation[16]. The role of glial-mediated neuroinflammation is also highlighted by these systems and enables the study of depression,

cognitive decline, and gastrointestinal dysfunction. Collectively, they offer information on PD pathophysiology, disease progression and therapeutic testing even though they cannot capture the complexity of human diseases.

3.1. Dopaminergic Degeneration

The models induced by neurotoxins, especially 6-Hydroxydopamine (6-OHDA) and MPTP, have played a significant role in the recreation of selective degeneration of dopaminergic neurons in the substantia nigra pars compacta, which is one of the core pathological changes in Parkinson disease (PD). The effect of these neurotoxins on the administration is a great loss of dopaminergic neurons and creates typical motor difficulties, including bradykinesia, rigidity, tremors, and postural instability[17]. Such motor deficiencies are very similar to those found in PD patients, and neurotoxin models are very useful models to study the pathophysiology of the disease and functional impact of dopaminergic loss. These models recreate the progressive neuronal degeneration observed with human PD and therefore serve as a useful tool to understand how motor dysfunction changes over time and to what extent in relation to dopaminergic loss.

Detailed research of the mechanisms underlying dopaminergic neurodegeneration is made possible at the molecular level by neurotoxin induced models. Investigations with the help of 6-OHDA and MPTP have shown that oxidative stress, mitochondrial dysfunction, neuroinflammation, and apoptosis play the crucial roles in neuronal loss[18]. Such models are also useful in the analysis of the potential neuroprotective approaches, such as pharmacological agents, gene therapies as well as antioxidant treatments, prior to clinical translation. Moreover, they enable researchers to analyze the combination of environmental toxins and genetic vulnerability, giving the information about multifactorial etiology of PD. In general, neurotoxin-induced models continue to be a pillar of preclinical research on PD that serves to fill the gap between fundamental mechanistic research and therapeutic development.

3.2. α-Synuclein Aggregation

Genetic models of PD (especially transgenic mice carrying mutated forms of alpha-synuclein e.g. A53T or A30P) have played a central role in the understanding of the involvement of protein misfolding and aggregation in the pathogenesis of PD. These mice have progressive motor impairment, loss of dopaminergic neurons and have Lewy body-like inclusions, which are similar to the pathological changes seen in human patients[19]. Genetic models provide researchers with an opportunity to study how proteins are misfolded, form intracellular inclusions, and become vulnerable to the neurons by recapitulating α-synuclein aggregation in vivo. They also offer a platform to investigate gene-environment interaction leading to increases in diseases progression and motor dysfunction.



Figure 3: α-Synuclein Aggregation

The a la carte of genetic methods with α-Synuclein pre-formed fibril (PFF) models has shown the prion-like spread of alpha-synuclein pathology through interconnected networks of neurons. Introduction of PFFs into the brains of rodents prompts endogenous aggregation of α-synuclein, which propagates through cell to cell and leads to progressive death of dopaminergic neurons[20]. Such models in particular can be useful in the study of the dynamics of inclusion formation, cellular trafficking of misfolded proteins, and the resultant effect on the functioning and integrity of the neuronal networks. Combined, genetic and PFF models are essential in terms of understanding how PD occurs at the molecular and cellular level and can be used to create and launch therapeutic interventions that can address α-synuclein pathology.

3.3. Neuroinflammation

Parkinson animal models have also given great information on how neuroinflammation develops the disease. These researches show that glial cell activation (microglia and astrocytes) leads to the release of pro-inflammatory cytokines and chemokines[21]. This prolonged inflammatory state reinforces oxidative stress, mitochondrial dysfunction and synaptic disruption which further enhances the loss of dopaminergic neurons in the substantia nigra. These models can be used to understand the interplay between immune mechanisms and neuronal pathology to promote disease progression in human PD by imitating elements of the neuroinflammatory response in human PD.



Figure 4: Neuroinflammation[22].

Persistent neuroinflammatory conditions do not only hasten the process of neuronal degeneration, but also predispose the dopaminergic neurons to other forms of stressors, including the presence of α-synuclein aggregates and environmental toxins[23]. Neuroinflammation, which occurs in response to peripheral cytokines such as tumor necrosis factor, has been suggested as a possible therapeutic target in animal research to reduce neuronal death and enhance motor performance. The article prioritizes the role of the immune system and neurodegeneration as a complex process and neuroinflammation as one of the major pathological processes in PD and a possible focus of therapy to delay the progression of the disease.

3.4. Non-Motor Symptoms

Although motor impairment is the characteristic feature of the Parkinson disease, non-motor manifestation also has a great influence on the quality of life of patients, and animal models have become necessary to examine these aspects[24]. Neurotoin, genetic and α-synuclein PFF systems models of PD have shown behavioral and physiological alterations resembling human non-motor-related changes, such as depression-like and anxiety-like behaviors, cognitive impairment, and gastrointestinal disturbance. The study of these models will help researchers to determine the neural circuits, neurotransmitter systems, and molecular pathways underlying non-motor symptoms, and will give a more comprehensive picture of the pathology of PD other than the dopaminergic one.

The analysis of possible interventions aimed at the treatment of non-motor symptoms, which is also poorly treated with conventional dopaminergic therapies, is another aspect that animal studies can help to evaluate[25]. As an example, antidepressants, cognitive enhancers, and gut-targeted therapies have been tested in preclinical models and provided a set of new findings on the potential mechanisms that can relieve non-motor manifestations. The investigation of these symptoms in animal models highlights the systemic characteristics of PD and emphasizes the necessity of the comprehensive treatment methods that enhance the motor functions of the patients as well as their quality of life.

3. THERAPEUTIC INTERVENTIONS AND NEUROPROTECTIVE STRATEGIES IN ANIMAL MODELS

Animal models of Parkinson disease (PD) are important platforms of testing therapeutic interventions and discussing neuroprotective interventions prior to clinical translation. The models that researchers can use to assess the effectiveness of pharmacological agents in reversing motor deficits and delaying the loss of dopaminergic neurons include models induced by neurotoxins, including 6-OHDA and MPTP[26]. These have been extensively applied in testing dopaminergic therapies such as L-DOPA, dopamine agonists, and monoamine oxidase inhibitors which are designed to replenish the dopamine levels or to augment neurotransmission within the nigro striatal pathway. In addition to symptomatic help, these models are useful in the development of disease-modifying therapies that involve the oxidative stress, mitochondrial dysfunction, and apoptosis, which provide the possible approach to slow down or prevent neurodegeneration.

Genetic and α-synuclein pre-formed fibril (PFF) models have offered models on which interventions should be tested on protein aggregation, and prion like propagation of 51-synuclein pathology[27]. Small molecules used as therapeutic agents in these models prevent the aggregation of α-synuclein, immunotherapies to misfolded proteins, and gene therapies that decrease the expression of α-synuclein or increase the ability of cells to clear these aggregates as a way of aiding in the elimination of aggregates of the protein includes autophagy and proteasomal degradation. These experiments contribute to the understanding of how protein misfolding can cause neuronal dysfunction and how it is possible to prevent/ reverse the formation of inclusions, which would eventually maintain dopaminergic activity.

Besides the targeting of neuronal pathology, animal models have also been used to study neuroinflammation as a therapeutic target. Microglial and astrocytes chronic activation is associated with dopaminergic vulnerability, and the means of glial activation regulation, blockage of pro-inflammatory cytokines or promoting anti-inflammatory signals have demonstrated promise in preclinical research[28]. Neuronal loss, motor functional improvement, and gene-editing approaches aimed at suppressing neuroinflammatory reactions can be used to reduce these effects and enhance the efficacy of protein aggregation-focused treatments.

The application of animal models in research on the strategies to mitigate non-motor symptoms of PD is also gaining more and more popularity[29]. Antidepressants, cognitive enhancers and gut-targeted therapies have also been tested under preclinical conditions in models that have depression-like behavior, cognitive deficits, and gastrointestinal dysfunction. Such interventions aid in the realization of the underlying neural and molecular pathophysiology of non-motor symptoms and give a foundation of total therapeutic treatment that fulfills both motor and non-motor features of PD, as well as enhances overall patient quality of life[30].

Table 1: Summary of Key Literature on Parkinson's Disease Pathogenesis and Clinical Manifestations

Author(s) & Year	Study	Focus Area	Methodology	Key Findings
Travagli, Browning, & Camilleri (2020)[31]	Parkinson disease and the gut: new insights into pathogenesis and clinical relevance	Gut–brain axis and gastrointestinal dysfunction in PD	Literature review of clinical and experimental studies	Gastrointestinal dysfunction often preceded motor symptoms; α-synuclein aggregation in the enteric nervous system was implicated; gut-related biomarkers and therapies were clinically relevant.
Troncoso-Escudero et al. (2018)[32]	Outside in: Unraveling the Role of Neuroinflammation in the Progression of Parkinson's Disease	Role of neuroinflammation in PD progression	Review of experimental and clinical evidence on immune system involvement	Neuroinflammation acted as both a consequence and driver of pathology; peripheral immune activation worsened neurodegeneration; inflammatory pathways presented therapeutic targets.
Vázquez-Vélez & Zoghbi (2021)[33]	Parkinson's disease genetics and pathophysiology	Genetic basis and molecular mechanisms of PD	Comprehensive review of genetic and molecular studies	Mutations in SNCA, LRRK2, and PARK genes linked to protein aggregation, mitochondrial dysfunction, and autophagy impairment; both monogenic and sporadic PD shared overlapping pathways.
Warnecke et al. (2022)[34]	Gastrointestinal involvement in Parkinson's disease: pathophysiology, diagnosis, and management	Gastrointestinal symptoms, diagnosis, and treatment in PD	Review of clinical evidence and diagnostic approaches	GI symptoms (e.g., constipation, delayed gastric emptying) were prevalent and often early; advanced tools enabled gut pathology assessment; integrated management strategies were recommended.
Weil & Reeves (2020)[35]	Hallucinations in Parkinson's disease: new insights into mechanisms and treatments	Neuropsychiatric symptoms, especially hallucinations, in PD	Literature review of clinical and neurobiological studies	Hallucinations linked to dopaminergic therapy, sensory disruption, and altered brain networks; management required balancing motor and psychiatric symptoms; emerging therapies targeted non-dopaminergic systems.

4. DISCUSSION

The models of Parkinson disease in animals have given invaluable information on the pathophysiological processes of dopaminergic degeneration, α-synuclein aggregation, neuroinflammation and non-motor symptoms[36]. These models offer researchers the opportunity to study disease progression and also test neuroprotective strategies by simulating important aspects of human PD, as well as accessing both motor and non-motor manifestations of a disease in a controlled experimental environment. The combination of results in neurotoxin-induced, genetic and α-synuclein PFF models provides an all-inclusive view of pathophysiology of PD and provides points of therapeutic intervention[37].

5.1. Interpretation and Analysis of Findings

The neurotoxin, genetic, and PFF model's analysis indicates the complexity of PD. The models of neurotoxins indicate that core motor symptoms can be recreated by selective loss of dopaminergic neurons only, which means that dopaminergic degeneration is particularly at the

center of clinical expression[38]. Genetic and PFF models offer important information on the misfolding of proteins, aggregation of 8-hydroxytryptophan and development of prion-like spread where mechanisms have been observed to promote progressive dysfunction and not just cell loss in neurons. The neuroinflammatory events evident in these models also depict the role of glial activation and chronic inflammation in making neurons susceptible. The discussion of non-motor symptoms of these models supports the fact that PD is systemic in its effects and involves many neural circuits and neurotransmitter systems. Together, these results confirm the applicability of animal models in explaining the cellular and systemic pathophysiology in PD[39].

5.2. Implications and Significance

The implications of these findings to translational research and therapeutic development are great. The definition of the processes of dopaminergic degeneration, 20-hydroxytryptophan, 20-hydroxytryptophanase, and neuroinflammation can inform the development of specific neuroprotective interventions, such as antioxidant interventions, anti-aggregative agents, immunotherapies, and anti-inflammatory therapeutic agents[40]. Also, non-motor symptom preclinical modeling, provides therapeutic opportunities on treating cognitive, emotional, and gastrointestinal dysfunctions, which many therapies do not focus on. Animal research offers mechanistic guidance on clinical trial design, enhances biomarker discovery, and contributes to the creation of comprehensive therapeutic strategies that are based on non-motor and motor components of PD[41].

5.3. Gaps and Future Research Directions

Although they contribute to this, there are limitations to present animal models. None of the models can be regarded as a perfect representation of human PD, especially the features of interaction between motor and non-motor symptoms, heterogeneity of the disease, and age-related development[42]. Neuroanatomy and molecular pathway species-differences can restrict translational applicability and most models do not reflect late neurodegeneration or progressive clinical progression[43]. Further studies are needed to come up with models that better repriculate human PD such as inducible models, aged animals and combination models where genetic vulnerability and environmental stress factors interact. Also, the enhanced imaging, omics technology, and longitudinal behavioral measurements can be introduced to enhance the mechanistic knowledge and enable the discovery of the early biomarkers[44]. The study of the connections among α-synuclein pathology, neuroinflammation, and non-dopaminergic neuronal systems also can provide new therapeutic targets[45].

5. CONCLUSION

The animal models of Parkinson disease including neurotoxin-induced, genetic, and pre-formed fibrils (PFF) systems of α-synuclein have been central to our current knowledge on the complexity and multifactorial pathophysiology of PD. These models have given a comprehensive understanding of the selective degeneration of dopaminergic cells within the substantia nigra, accumulation and prion like propagation of the α-synuclein and also the role of chronic neuroinflammation of the glial cells. Moreover, they have emphasized the systemic character of PD by bringing out the non-motor expression of PD through cognitive impairments, mood changes and gastrointestinal dysfunction that have strong impacts on the quality of life of the patients. In addition to mechanistic understanding, these models are necessary platforms on which to appraise neuroprotective interventions, therapeutic

interventions, and novel interventions that address both motor and non-motor symptoms, such as antioxidant therapies, anti-aggregative compounds, immunomodulatory therapeutic interventions, and gut-targeted therapeutic interventions. On the whole, these models offer a strong platform on which to conduct preclinical testing, identify the possible biomarkers, and generate a more effective and holistic and translationally relevant treatment that would be able to alter the course of the disease and enhance patient outcomes.

REFERENCES

1. Abubakar, M. B., Sanusi, K. O., Ugusman, A., Mohamed, W., Kamal, H., Ibrahim, N. H., ... & Kumar, J. (2022). Alzheimer's disease: an update and insights into pathophysiology. Frontiers in aging neuroscience, 14, 742408.
2. Ahmad, M. H., Rizvi, M. A., Ali, M., & Mondal, A. C. (2023). Neurobiology of depression in Parkinson's disease: Insights into epidemiology, molecular mechanisms and treatment strategies. Ageing research reviews, 85, 101840.
3. Bari, B. A., Chokshi, V., & Schmidt, K. (2020). Locus coeruleus-norepinephrine: basic functions and insights into Parkinson's disease. Neural regeneration research, 15(6), 1006-1013.
4. Bloem, B. R., Okun, M. S., & Klein, C. (2021). Parkinson's disease. The Lancet, 397(10291), 2284-2303.
5. Calabresi, P., Di Lazzaro, G., Marino, G., Campanelli, F., & Ghiglieri, V. (2023). Advances in understanding the function of alpha-synuclein: implications for Parkinson's disease. Brain, 146(9), 3587-3597.
6. Ciurea, A. V., Mohan, A. G., Covache-Busuioc, R. A., Costin, H. P., Glavan, L. A., Corlatescu, A. D., & Saceleanu, V. M. (2023). Unraveling molecular and genetic insights into neurodegenerative diseases: advances in understanding Alzheimer's, Parkinson's, and Huntington's diseases and amyotrophic lateral sclerosis. International journal of molecular sciences, 24(13), 10809.
7. Dirkx, M. F., & Bologna, M. (2022). The pathophysiology of Parkinson's disease tremor. Journal of the Neurological Sciences, 435, 120196.
8. Farotti, L., Paolini Paoletti, F., Simoni, S., & Parnetti, L. (2020). Unraveling pathophysiological mechanisms of Parkinson's disease: contribution of CSF biomarkers. Biomarker insights, 15, 1177271920964077.
9. Gao, C., Liu, J., Tan, Y., & Chen, S. (2020). Freezing of gait in Parkinson's disease: pathophysiology, risk factors and treatments. Translational neurodegeneration, 9(1), 12.
10. Guatteo, E., Berretta, N., Monda, V., Ledonne, A., & Mercuri, N. B. (2022). Pathophysiological features of nigral dopaminergic neurons in animal models of Parkinson's disease. International journal of molecular sciences, 23(9), 4508.
11. Ikram, M., Park, T. J., Ali, T., & Kim, M. O. (2020). Antioxidant and neuroprotective effects of caffeine against Alzheimer's and Parkinson's disease: Insight into the role of Nrf-2 and A2AR signaling. Antioxidants, 9(9), 902.
12. Jamwal, S., & Kumar, P. (2019). Insight into the emerging role of striatal neurotransmitters in the pathophysiology of Parkinson's disease and Huntington's disease: a review. Current neuropharmacology, 17(2), 165-175.
13. Jankovic, J., & Tan, E. K. (2020). Parkinson's disease: etiopathogenesis and treatment. Journal of Neurology, Neurosurgery & Psychiatry, 91(8), 795-808.

14. Jia, F., Fellner, A., & Kumar, K. R. (2022). Monogenic Parkinson's disease: genotype, phenotype, pathophysiology, and genetic testing. Genes, 13(3), 471.

15. Kaur, R., Mehan, S., & Singh, S. (2019). Understanding multifactorial architecture of Parkinson's disease: pathophysiology to management. Neurological Sciences, 40(1), 13-23.

16. Lee, H. S., Lobbestael, E., Vermeire, S., Sabino, J., & Cleynen, I. (2021). Inflammatory bowel disease and Parkinson's disease: common pathophysiological links. Gut, 70(2), 408-417.

17. Ma, A., Lau, K. K., & Thyagarajan, D. (2020). Voice changes in Parkinson's disease: What are they telling us?. Journal of Clinical Neuroscience, 72, 1-7.

18. Marino, B. L., de Souza, L. R., Sousa, K. P., Ferreira, J. V., Padilha, E. C., da Silva, C. H., ... & Hage-Melim, L. I. (2020). Parkinson's disease: a review from pathophysiology to treatment. Mini reviews in medicinal chemistry, 20(9), 754-767.

19. Martins Jr, A. C., Morcillo, P., Ijomone, O. M., Venkataramani, V., Harrison, F. E., Lee, E., ... & Aschner, M. (2019). New insights on the role of manganese in Alzheimer's disease and Parkinson's disease. International journal of environmental research and public health, 16(19), 3546.

20. Masato, A., Plotegher, N., Boassa, D., & Bubacco, L. (2019). Impaired dopamine metabolism in Parkinson's disease pathogenesis. Molecular neurodegeneration, 14(1), 35.

21. Morris, H. R., Spillantini, M. G., Sue, C. M., & Williams-Gray, C. H. (2024). The pathogenesis of Parkinson's disease. The Lancet, 403(10423), 293-304.

22. Pan, L., Meng, L., He, M., & Zhang, Z. (2021). Tau in the pathophysiology of Parkinson's disease. Journal of Molecular Neuroscience, 71(11), 2179-2191.

23. Park, J. S., Davis, R. L., & Sue, C. M. (2018). Mitochondrial dysfunction in Parkinson's disease: new mechanistic insights and therapeutic perspectives. Current neurology and neuroscience reports, 18(5), 21.

24. Raj, K., Kaur, P., Gupta, G. D., & Singh, S. (2021). Metals associated neurodegeneration in Parkinson's disease: Insight to physiological, pathological mechanisms and management. Neuroscience Letters, 753, 135873.

25. Rani, L., Sahu, M. R., & Mondal, A. C. (2022). Age-related mitochondrial dysfunction in Parkinson's disease: new insights into the disease pathology. Neuroscience, 499, 152-169.

26. Rocha, E. M., De Miranda, B., & Sanders, L. H. (2018). Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson's disease. Neurobiology of disease, 109, 249-257.

27. Sayyaed, A., Saraswat, N., Vyawahare, N., & Kulkarni, A. (2023). A detailed review of pathophysiology, epidemiology, cellular and molecular pathways involved in the development and prognosis of Parkinson's disease with insights into screening models. Bulletin of the National Research Centre, 47(1), 70.

28. See, W. Z. C., Naidu, R., & Tang, K. S. (2022). Cellular and molecular events leading to paraquat-induced apoptosis: mechanistic insights into Parkinson's disease pathophysiology. Molecular neurobiology, 59(6), 3353-3369.

29. Tan, J. S. Y., Chao, Y. X., Rötzschke, O., & Tan, E. K. (2020). New insights into immune-mediated mechanisms in Parkinson's disease. International Journal of Molecular Sciences, 21(23), 9302.

30. Thomas, G. E., Zarkali, A., Ryten, M., Shmueli, K., Gil-Martinez, A. L., Leyland, L. A., ... & Weil, R. S. (2021). Regional brain iron and gene expression provide insights into neurodegeneration in Parkinson's disease. Brain, 144(6), 1787-1798.

31. Travagli, R. A., Browning, K. N., & Camilleri, M. (2020). Parkinson disease and the gut: new insights into pathogenesis and clinical relevance. Nature Reviews Gastroenterology & Hepatology, 17(11), 673-685.

32. Troncoso-Escudero, P., Parra, A., Nassif, M., & Vidal, R. L. (2018). Outside in: Unraveling the Role of Neuroinflammation in the Progression of Parkinson's Disease. Frontiers in neurology, 9, 860.

33. Vázquez-Vélez, G. E., & Zoghbi, H. Y. (2021). Parkinson's disease genetics and pathophysiology. Annual review of neuroscience, 44(1), 87-108.

34. Warnecke, T., Schäfer, K. H., Claus, I., Del Tredici, K., & Jost, W. H. (2022). Gastrointestinal involvement in Parkinson's disease: pathophysiology, diagnosis, and management. NPJ Parkinson's disease, 8(1), 31.

35. Weil, R. S., & Reeves, S. (2020). Hallucinations in Parkinson's disease: new insights into mechanisms and treatments. Advances in clinical neuroscience & rehabilitation: ACNR, 19(4), ONNS5189.

36. Wichmann, T. (2019). Changing views of the pathophysiology of Parkinsonism. Movement Disorders, 34(8), 1130-1143.

37. Verma VS. Development of Multi-Target Directed Ligands for Neurodegenerative Disorders: A Medicinal Chemistry Approach. Interconnected Journal of Chemistry and Pharmaceutical Sciences (IJCPS). 2025;01:49–65.

38. Wüllner, U., Borghammer, P., Choe, C. U., Csoti, I., Falkenburger, B., Gasser, T., ... & Riederer, P. (2023). The heterogeneity of Parkinson's disease. Journal of neural transmission, 130(6), 827-838.

39. Kumar, D. ., & Yadav, K. . (2025). Protective Effect of a New Herbal Remedy on A Parkinson's Disease Model in Rats. International Journal of Pharmacognosy and Herbal Drug Technology, 2(1), 38-48.

40. Zaman, V., Shields, D. C., Shams, R., Drasites, K. P., Matzelle, D., Haque, A., & Banik, N. L. (2021). Cellular and molecular pathophysiology in the progression of Parkinson's disease. Metabolic brain disease, 36(5), 815-827.

41. Kumar, D. (2025). The Impact of Virtual Reality-Based Physiotherapy on Stroke Rehabilitation Outcomes. Current Research in Dental, Physiotherapy and Pharmaceutical Sciences (CRDPPS), 1(1), 46-62.

42. Zhang, G., Xia, Y., Wan, F., Ma, K., Guo, X., Kou, L., ... & Wang, T. (2018). New perspectives on roles of alpha-synuclein in Parkinson's disease. Frontiers in aging neuroscience, 10, 370.

43. Kumar, D. ., & Yadav, K. . (2025). Protective Effect of a New Herbal Remedy on A Parkinson's Disease Model in Rats. International Journal of Pharmacognosy and Herbal Drug Technology, 2(1), 38-48.

44. Zhou, Z. D., Yi, L. X., Wang, D. Q., Lim, T. M., & Tan, E. K. (2023). Role of dopamine in the pathophysiology of Parkinson's disease. Translational neurodegeneration, 12(1), 44.

45. Kumar, D. . (2025). Behavioral and Biochemical Analysis of a Dual-Target CNS Agent Using Rodent Maze Models. Journal of Pharmaceutical Research and Integrated Medical Sciences, 2(5), 01-15.